Chronic Idiopathic Urticaria Clinical Trial
Official title:
A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)
This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02814630 -
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
|
N/A | |
| Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT03183024 -
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
|
Phase 4 | |
| Completed |
NCT00757562 -
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
|
Phase 3 | |
| Completed |
NCT03858634 -
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
|
Phase 2 | |
| Completed |
NCT01292473 -
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
|
Phase 3 | |
| Completed |
NCT00866788 -
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
|
Phase 2 | |
| Recruiting |
NCT01635127 -
Efficacy Study of Canakinumab to Treat Urticaria
|
Phase 2 | |
| Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
| Not yet recruiting |
NCT02166151 -
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
|
Phase 3 | |
| Recruiting |
NCT02031679 -
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
|
Phase 2 | |
| Recruiting |
NCT00346606 -
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
|
Phase 4 | |
| Completed |
NCT01264939 -
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
|
Phase 3 | |
| Completed |
NCT01287117 -
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
|
Phase 3 | |
| Completed |
NCT03406325 -
Mast Cell Activation Test in Allergic Disease
|
||
| Not yet recruiting |
NCT04175704 -
Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria
|
Phase 1 | |
| Withdrawn |
NCT01030120 -
Etanercept for the Treatment of Chronic Urticaria
|
Phase 2/Phase 3 | |
| Completed |
NCT00264303 -
CUTE (Chronic Urticaria Treatment Evaluation)
|
Phase 4 | |
| Recruiting |
NCT05774639 -
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
|
Phase 3 | |
| Completed |
NCT01599637 -
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
|
Phase 2 |